Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-744 |
Synonyms | |
Therapy Description |
ABBV-744 is a bromodomain II selective BET inhibitor, which potentially inhibits tumor cell proliferation and decreases tumor growth (Cancer Res 2018;78(13 Suppl):Abstract nr DDT01-05, PMID: 31969702, PMID: 32324999). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-744 | ABBV744|ABBV 744 | BET Inhibitor (Pan) 32 | ABBV-744 is a bromodomain II selective BET inhibitor, which potentially inhibits tumor cell proliferation and decreases tumor growth (Cancer Res 2018;78(13 Suppl):Abstract nr DDT01-05, PMID: 31969702, PMID: 32324999). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03360006 | Phase I | ABBV-744 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Advanced Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer | Terminated | USA | 0 |
NCT04454658 | Phase I | ABBV-744 ABBV-744 + Navitoclax ABBV-744 + Ruxolitinib | Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | Active, not recruiting | USA | TUR | SWE | ITA | ISR | HUN | ESP | BRA | BGR | AUS | ARG | 3 |